Literature DB >> 12938219

Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigen.

Reinhold Schirmbeck1, Waltraud Böhm, Nicolas Fissolo, Karl Melber, Jörg Reimann.   

Abstract

The small hepatitis B surface antigen (HBsAg) of hepatitis B virus (HBV) has limited variability, but some serotypes and genotypes have been defined. Although no biological or pathogenetic differences could be traced to HBV serotypes, the clinical picture, response to treatment and long-term prognosis of HBV infection may vary with the HBV genotype, possibly due to differences in specific T cell recognition of HBV antigens from different genotypes. We analyzed murine CD8(+) T cell responses to two K(b)-restricted HBsAg epitopes primed by four different HBsAg variants using protein- and DNA-based vaccination protocols. The K(b)-binding S(208-215) epitope 1 is processed from exogenous but not endogenous HBsAg. Variants of epitope 1 differing at two positions within the epitope (ILSPFLPL in ayw/adr versus IVSPFIPL in adw2) efficiently primed cross-reactive CD8(+) T cell responses. In contrast, the exchange of an N-terminal flanking residue (S to N) completely eliminated the immunogenicity of epitope 1. The K(b)-binding S(190-197) epitope 2 is processed from endogenous but not exogenous HBsAg. A single-residue exchange within the epitope (VWLSVIWM in ayw/adr versus VWLSAIWM in adw2) completely eliminated the immunogenicity of epitope 2. Single, conservative residue exchanges can thus give rise to diverging CD8(+) T cell repertoires, suggesting an impressive complexity and flexibility of the CD8(+) T cell repertoire to antigen variants from viruses with limited diversity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938219     DOI: 10.1002/eji.200324125

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Different sources of "help" facilitate the antibody response to hepatitis D virus delta antigen.

Authors:  Peter Seizer; Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2004-11-10       Impact factor: 4.599

3.  Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in mice.

Authors:  Ren Zhu; Maryline Mancini-Bourgine; Xiao Ming Zhang; Florence Bayard; Qiang Deng; Marie-Louise Michel
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

4.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

5.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

6.  Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups.

Authors:  Jing Ning; Jianwen Wang; Huiling Zheng; Siwen Peng; Tianhao Mao; Lu Wang; Guangxin Yu; Jia Liu; Shuang Liu; Ting Zhang; Shigang Ding; Fengmin Lu; Xiangmei Chen
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

7.  A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Authors:  Melissa A Cobleigh; Xin Wei; Michael D Robek
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

8.  Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.

Authors:  Tracy D Reynolds; Linda Buonocore; Nina F Rose; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

9.  Computer-aided prediction of antigen presenting cell modulators for designing peptide-based vaccine adjuvants.

Authors:  Gandharva Nagpal; Kumardeep Chaudhary; Piyush Agrawal; Gajendra P S Raghava
Journal:  J Transl Med       Date:  2018-07-03       Impact factor: 5.531

10.  A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

Authors:  Thomas H King; Charles B Kemmler; Zhimin Guo; Derrick Mann; Yingnian Lu; Claire Coeshott; Adam J Gehring; Antonio Bertoletti; Zi Z Ho; William Delaney; Anuj Gaggar; G Mani Subramanian; John G McHutchison; Shikha Shrivastava; Yu-Jin L Lee; Shyamasundaran Kottilil; Donald Bellgrau; Timothy Rodell; David Apelian
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.